Emmanuelle Meuillet
Chief Scientific Officer at Microvascular Therapeutics - , Arizona, United States
Emmanuelle Meuillet's Colleagues at Microvascular Therapeutics
Emmanuelle Meuillet's Contact Details
Tucson,Arizona,United States
Microvascular Therapeutics
Emmanuelle Meuillet's Company Details
Microvascular Therapeutics is a clinical stage biotechnology which pioneers in ultrasound contrast agents and theranostics. We are looking for funds in order to further develop our two main products in 4 therapeutic indications including cardiovascular. We have a bridge loan open for up to $5M. We have several follow-on products derived from the platform technology. Microvascular Therapeutics (MVT) is developing a new improved ultrasound contrast agent MVT-100 via the 505(b)(2) pathway. The founders of MVT developed Definity®, the world's #1 selling ultrasound contrast agent. Definity requires refrigerated temperature storage and has side effect of back pain. MVT-100 is a room temperature storage product and designed to eliminate the back pain. MVT has multiple theranostic products in its pipeline with multi-billion dollar market potential, the first one of which is expected to be regulated via the device pathway. MVT has 5 active NIH grants. MVT has an open Bridge Round at very favorable terms.